Senti Biosciences Holdings (SNTI) Operating Leases (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Operating Leases of $28.9 million for Q4 2025, little changed year-over-year from $28.9 million in Q4 2024, and down 4.08% quarter-over-quarter from $30.1 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Operating Leases (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Operating Leases history runs 5 years deep, the most recent figure standing at $28.9 million for Q4 2025.
- In Q4 2025, Operating Leases changed 0.0% year-over-year to $28.9 million; the TTM figure through Dec 2025 stood at $28.9 million (changed 0.0% YoY), while the FY2025 annual figure was $28.9 million, changed 0.0% from the prior year.
- Operating Leases for Q4 2025 stood at $28.9 million, down from $30.1 million in the prior quarter.
- The five-year high for Operating Leases was $38.1 million in Q2 2023, with the low at $21.0 million in Q4 2021.
- The 5-year median for Operating Leases is $31.7 million (2022), against an average of $32.1 million.
- The sharpest annual moves came in 2022 and 2025: Operating Leases surged 67.25% in 2022, then fell 24.54% in 2025.
- Senti Biosciences Holdings' Operating Leases stood at $21.0 million in 2021, then surged by 67.25% to $35.1 million in 2022, then retreated by 4.46% to $33.5 million in 2023, then decreased by 13.86% to $28.9 million in 2024, then changed by 0.0% to $28.9 million in 2025.
- Business Quant data shows SNTI's Operating Leases at $28.9 million in Q4 2025, $30.1 million in Q3 2025, and $31.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.64 Bn | 130.78 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.89 Bn | 77.90 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.11 Bn | 59.93 Bn | 1.37 Bn |
| 4 | Moderna | 55.83 Bn | 50.69 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.01 Bn | 36.91 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.63 Bn | 28.32 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.65 Bn | 9.26 Bn | 668.28 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - |
| 10 | Senti Biosciences Holdings | 11.80 Mn | 11.80 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 28.89 Mn |
| Sep 30, 2025 | 30.12 Mn |
| Jun 30, 2025 | 31.31 Mn |
| Mar 31, 2025 | 27.63 Mn |
| Dec 31, 2024 | 28.89 Mn |
| Sep 30, 2024 | 34.61 Mn |
| Jun 30, 2024 | 31.31 Mn |
| Mar 31, 2024 | 36.62 Mn |
| Dec 31, 2023 | 33.54 Mn |
| Sep 30, 2023 | 37.19 Mn |
| Jun 30, 2023 | 38.10 Mn |
| Mar 31, 2023 | 37.92 Mn |
| Dec 31, 2022 | 35.10 Mn |
| Sep 30, 2022 | 32.17 Mn |
| Jun 30, 2022 | 29.02 Mn |
| Dec 31, 2021 | 20.99 Mn |